Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
Zacks News
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture
by Zacks Equity Research
Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.
Charles River (CRL) to Build RightSource Lab With New Pact
by Zacks Equity Research
Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Why Is Charles River (CRL) Down 14.8% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River's (CRL) New Cloud Platform Offers Real-Time Data
by Zacks Equity Research
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
Charles River (CRL) Advances CDMO Portfolio With Latest Offer
by Zacks Equity Research
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes
by Zacks Equity Research
The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
by Zacks Equity Research
Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
Charles River Laboratories (CRL) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InnovAge Holding Corp. (INNV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 36.36% and 1.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
by Zacks Equity Research
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
Charles River (CRL) to Develop RNA-based Therapy With New Pact
by Zacks Equity Research
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
Charles River (CRL) to Advance DNA Programs With New Launch
by Zacks Equity Research
Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.
Should You Buy Charles River Laboratories (CRL) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.
Charles River (CRL) Benefits From Price Rise Amid FX Woe
by Zacks Equity Research
Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.